Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case.
Autores: Sergio I. Prada, Victoria E. Soto, Tatiana S. Andia, Claudia P. Vaca, Álvaro A. Morales, Sergio R. Márquez and Alejandro Gaviria.
Journal: Cost Effectiveness and Resource Allocation.
Publicado: Mayo de 2018.
High pharmaceutical expenditure is one of the main concerns for policymakers worldwide. In Colombia, a middle-income country, outpatient prescription represents over 10% of total health expenditure in the mandatory benefts package (POS), and close to 90% in the complementary government fund (No POS). In order to control expenditure, since 2011, the Ministry of Health introduced price caps on inpatient drugs reimbursements by active ingredient. By 2013, more than 400 diferent products, covering 80% of public pharmaceutical expenditure were controlled. This paper investigates the efects of the Colombian policy eforts to control expenditure by controlling prices.